In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah® (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
from Latest Science News -- ScienceDaily https://ift.tt/2Q7y3t5
via IFTTT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment